SCHEMBL9612031

SCHEMBL9612031

CC(C)(N)c1ccc(N)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.48
CYP3A4 P08684 6/20 0.48
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 1/20 0.46
PDE2A O00408 3/20 0.42
GAA P10253 2/20 0.40
RECQL P46063 2/20 0.39
ALOX15 P16050 2/20 0.39
ESR2 Q92731 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30279249 0.84 ALDH1A1 (0.52) TSHRCYP3A4ALDH1A1MAPK1GAA
SCHEMBL2811051 0.84 TSHR (0.50) TSHRCYP3A4ALDH1A1MAPK1GAA
SCHEMBL2963375 0.84 ALDH1A1 (0.52) TSHRCYP3A4ALDH1A1MAPK1GAA
SCHEMBL7877357 0.83 TSHR (0.48) TSHRCYP3A4ALDH1A1PDE2AGAA
SCHEMBL22280536 0.83 CYP3A4 (0.48) TSHRCYP3A4ALDH1A1MAPK1GAA
SCHEMBL2796185 0.82 TSHR (0.56) TSHRCYP3A4PDE2AHSD17B10AKT1
SCHEMBL14307623 0.81 TSHR (0.46) TSHRCYP3A4ALDH1A1MAPK1PDE2A
SCHEMBL31053156 0.80 CYP3A4 (0.50) TSHRCYP3A4ALDH1A1MAPK1PDE2A
Hydrochloric Acid SCHEMBL11541806 0.80 TSHR (0.54) TSHRCYP3A4PDE2AHSD17B10AKT1
SCHEMBL119351 0.80 CYP3A4 (0.50) TSHRCYP3A4ALDH1A1MAPK1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8198458-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-12 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135929-A1 Methods Of Modulating Uric Acid Levels XDH, PON1, OAT TSHR 2863/4885CYP3A4 2395/4885ALDH1A1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.